Clinical trials: Rosuvastatin
Organic Anion Transporting Polypeptide1B1 (OATP1B1), Rosuvastatin
Influence of Organic Anion Transporting Polypeptide1B1(OATP1B1) Genotype on Rosuvastatin PK, PD and Lipid Profiles
This study aimed to explore the influence of organic anion transporting polypeptide1B1 (OATP1B1) genotype on pharmacokinetics, lipid lowering effect and lipid profiles after rosuvastatin administration.
- Trial name
- OATP (NCT01218347)
- Testing
- Rosuvastatin
- Where
- South Korea
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Seoul National University Hospital
Obesity & Overweight, Bariatric Surgery
Rosuvastatin and Losartan Pharmacokinetics After Bariatric Surgery
This prospective, open-label, non-randomized pharmacokinetic study will evaluate how Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy affect systemic exposure to single oral test doses of rosuvastatin and losartan.
- Conditions
- Obesity & Overweight, Bariatric Surgery, Pharmacokinetics After Oral Intake, Drug Absorption
- Trial name
- BARI-PK (NCT07748273)
- Testing
- Rosuvastatin, Losartan (Control)
- Where
- Brazil
- Volunteers
- 60 people
- Sponsor
- Hospital das Clínicas de Ribeirão Preto
Atherosclerosis, HIV Infections
Effectiveness of Rosuvastatin at Preventing the Progression of Atherosclerosis in HIV Positive Patients
Rosuvastatin is a drug used to lower cholesterol, which also has other cardiovascular benefits. The goal of this project is to determine if rosuvastatin is effective at slowing the development of heart disease in people with HIV.
- Trial name
- NCT00673582
- Testing
- Rosuvastatin
- Where
- Canada
- Volunteers
- 250 people
- Sponsor
- University of British Columbia
Hypercholesterolemia
Study of Efficacy, Safety, Tolerability and Quality of Life of Inclisiran (KJX839) vs Placebo, on Top of Ongoing Individually Optimized Lipid-lowering Therapy, in Participants With Hypercholesterolemia
Study of efficacy, safety, tolerability and quality of life of inclisiran (KJX839) vs placebo, on top of ongoing individually optimized lipid-lowering therapy, in participants with hypercholesterolemia
- Trial name
- V-DIFFERENCE (NCT05192941)
- Testing
- Inclisiran Sodium
- Where
- 136 sites in Bulgaria, Czechia and 6 more
- Volunteers
- 1,770 people
- Sponsor
- Novartis Pharmaceuticals
Arterial Hypertension
Rosuvastatin for Preventing Complications in Renal Ablation
The primary objective of this study is to test the hypothesis that twice overnight high-dose rosuvastatin loading before RNA followed by 3-month treatment with regular doses of rosuvastatin can reduce both the acute and late…
- Trial name
- ARTEMISIA (NCT01899027)
- Testing
- Rosuvastatin
- Where
- Italy
- Volunteers
- 112 people
- Sponsor
- University of Roma La Sapienza
Intracranial Arterial Diseases
Rosuvastatin Treatment for Intracranial Arterial Stenosis Based on Magnetic Resonance Angiography
The purpose of this study is to investigate the effects of rosuvastatin treatment on degree of intracranial arterial stenosis.
- Trial name
- NCT02341794
- Testing
- Rosuvastatin
- Where
- Japan
- Volunteers
- 60 people
- Sponsor
- Tokyo Medical University
Breast Cancer
Rosuvastatin to Lower Circulating Tissue Factor Bearing Microparticles in Metastatic Breast Cancer
Research studies have shown a strong association between cancer and blood clots in the veins (also known as deep vein thrombosis).
- Trial name
- NCT01299038
- Testing
- rosuvastatin
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Beth Israel Deaconess Medical Center
Anthracycline-induced Cardiac Toxicity, Breast Cancer
Rosuvastatin for Prevention of Anthracycline-induced Cardiac Dysfunction in Breast Cancer Patients
This study, called "ROSUBREAST", is a multicenter, double-blind, randomized clinical trial evaluating whether rosuvastatin (20 mg daily) can protect the heart in women with breast cancer receiving anthracycline-based…
- Conditions
- Anthracycline-induced Cardiac Toxicity, Breast Cancer, Anthracycline Related Cardiotoxicity in Breast Cancer, Anthracycline-induced Cardiotoxicity
- Trial name
- ROSUBREAST (NCT07254221)
- Testing
- Rosuvastatin 20 mg/day
- Where
- 7 sites in Iran
- Volunteers
- 400 people
- Sponsor
- Shiraz University of Medical Sciences
Dyslipidemia Associated With Type II Diabetes Mellitus
Efficacy and Safety of Berlim 25/20 Association in the Treatment of Type II Diabetes Mellitus and Dyslipidemia.
The purpose of this study is to evaluate the efficacy and safety of Berlim 25/20 association in the treatment of type 2 diabetes mellitus and dyslipidemia.
- Trial name
- NCT04602754
- Testing
- BERLIM 25/20 ASSOCIATION, EMPAGLIFLOZIN, ROSUVASTATIN CALCIUM
- Where
- Brazil
- Volunteers
- 228 people
- Sponsor
- EMS
Dyslipidemia Associated With Type II Diabetes Mellitus
Type 2 Diabetic Patients Maintained on Statin Therapy
Patients with diabetes mellitus (DM) are at increased risk of atherosclerotic cardiovascular disease (ACVD). The achievement of the LDL-C target with statins for the reduction of ACVD risk is recommended.
- Trial name
- NCT03784703
- Testing
- Atorvastatin 40 Mg Oral Tablet, Rosuvastatin 10 Mg Oral Tablet
- Where
- Egypt
- Volunteers
- 160 people
- Sponsor
- Damanhour University
Deep Vein Thrombosis, Pulmonary Embolism
Rosuvastatin Use to Improve the Coagulation Profile in Patients With Venous Thrombosis
Epidemiological studies have shown a 2-3 fold increased long-term risk of arterial cardiovascular disease after venous thrombosis, most predominant in the first year following initial venous thrombosis.
- Trial name
- START (NCT01613794)
- Testing
- Rosuvastatin
- Where
- 3 sites in Netherlands
- Volunteers
- 255 people
- Sponsor
- Leiden University Medical Center
Chronic Periodontitis
Platelet-rich Fibrin With 1.2% Rosuvastatin in Chronic Periodontitis Treatment
The present study is designed to evaluate the combined efficacy of Platelet Rich Fibrin (PRF) and 1.2% Rosuvastatin (RSV) with open flap debridement (OFD) in treatment of intrabony defects in chronic periodontitis patients
- Trial name
- NCT02645227
- Testing
- Open flap debridement (OFD), OFD with Platelet rich fibrin (PRF), OFD with PRF and 1.2% Rosuvastatin
- Where
- India
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Government Dental College and Research Institute, Bangalore
Renal Insufficiency
Pharmacokinetics of Midazolam, Dabigatran, Pitavastatin, Atorvastatin, and Rosuvastatin in Participants With Renal Insufficiency in the Presence and Absence of Rifampin (MK-0000-386)
The purpose of this open-label, 2-period, fixed-sequence study is to characterize the plasma pharmacokinetic profiles of midazolam, dabigatran, pitavastatin, atorvastatin, and rosuvastatin following a single oral dose…
- Trial name
- NCT03311841
- Testing
- Midazolam oral solution, Dabigatran and pitavastatin oral solution, Atorvastatin and rosuvastatin oral solution
- Where
- 2 sites in United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Healthy
Clinical Trial to Compare the Pharmacokinetics of DP-R208
A randomized, single-dose, open, crossover clinical trial to compare the pharmacokinetics of DP-R208 (Candesartan cilexetil and Rosuvastatin calcium fixed dose combinations) in comparison to each component administered alone in…
- Trial name
- NCT02707224
- Testing
- DP-R208, Candesartan cilexetil, Rosuvastatin
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Alvogen Korea
Hypertension, Dyslipidemias
The Efficacy and Safety of Triple Therapy of Telmisartan/Amlodipine/Rosuvastatin
The goal of this study was to assess the efficacy and safety of FDC therapy with triple therapy of Telmisartan 40 mg/Amlodipine 5 mg/Rosuvastatin 10mg in Korean patients with both hypertension and dyslipidemia.
- Trial name
- NCT03860220
- Testing
- NEWSTATIN TS, CADUET
- Where
- 9 sites in South Korea
- Volunteers
- 252 people
- Sponsor
- Hyo-Soo Kim
Carotid Artery Stenosis, Strokes
Statin Neuroprotection and Carotid Endarterectomy: Safety, Feasibility and Outcomes
The investigators hypothesize that pre-operative statin use is neuroprotective at maximal doses. The goals are to determine the safety, feasibility, and efficacy of maximizing statin doses for two weeks (12-18 days) prior to CEA…
- Trial name
- STANCE (NCT02850081)
- Testing
- Statin, Atorvastatin
- Where
- 7 sites in United States
- Volunteers
- 31 people
- Sponsor
- Columbia University
Atherosclerosis, Systemic Lupus Erythematosus
A Trial of Rosuvastatin in Systemic Lupus Erythematosus
Systemic Lupus Erythematosus (SLE) is a condition that affects the whole body. It can cause inflammation of the blood vessels resulting in an earlier thickening and hardening of the arteries resulting in strokes.
- Trial name
- NCT01170585
- Testing
- Rosuvastatin
- Where
- 2 sites in United Kingdom
- Volunteers
- 33 people
- Sponsor
- Imperial College London
Hyperlipidemia
Comparison of the Efficacy and Safety of Cresnon® and Crestor® in Patients With Hyperlipidemia
Comparison of the efficacy and safety of Cresnon® and Crestor® in patients with hyperlipidemia 8-week, active-controlled, open-label, randomized, parallelgroup, fixed-dose, noninferiority, multicenter, phase 4 design
- Trial name
- NCT02280590
- Testing
- Rosuvastatin(Cresnon®), Rosuvastatin(Crestor®)
- Where
- South Korea
- Volunteers
- 223 people
- Sponsor
- Dong-A ST Co., Ltd.
Hypercholesterolemia, Coronary Heart Disease
Evaluation of the Efficacy of Rosuvastatin in Daily Practice in Untreated High Risk Patients (CHALLENGE)
In an observational multi-centre study (CHALLENGE), the effects were assessed of starting treatment with low doses of rosuvastatin in statin naive patients with a history of coronary heart disease (CHD), peripheral vascular…
- Conditions
- Hypercholesterolemia, Coronary Heart Disease, Peripheral Vascular Disease, CVA
- Trial name
- CHALLENGE (NCT00574782)
- Volunteers
- 2,660 people
- Sponsor
- AstraZeneca
Pharmacokinetics and Drug Interaction of Crestor and Glucodown SR
A Phase 1 Clinical Trial to Investigate Pharmacokinetics and Drug Interaction of Crestor and Glucodown OR SR in Healthy Volunteers
This clinical trial is designed to compare the pharmacokinetic characteristics of combination and separate administration of Crestor(Rosuvastatin) and Glucodown(Metformin SR).
- Trial name
- NCT01526317
- Testing
- Crestor 10mg(Rosuvastatin 10mg), Glucodown OR SR 750mg(Metformin SR 750mg)
- Where
- South Korea
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Yuhan Corporation